Charles Schwab
AGRX

Charles Schwab’s Agile Therapeutics AGRX Stock Holding History

Charles Schwab’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-16
Closed -$42K – 3565
2021
Q2 		$42K Sell
16
-74
-82% -$244K ﹤0.01% 3395
2021
Q1 		$376K Buy
90
+4
+5% +$21.6K ﹤0.01% 3177
2020
Q4 		$495K Hold
86
– – ﹤0.01% 2998
2020
Q3 		$524K Sell
86
-3
-3% -$17.2K ﹤0.01% 2865
2020
Q2 		$494K Buy
+89
New +$462K ﹤0.01% 2834
2017
Q2 		– Sell
-7
Closed -$44K – 3153
2017
Q1 		$44K Hold
7
– – ﹤0.01% 3043
2016
Q4 		$77K Hold
7
– – ﹤0.01% 3055
2016
Q3 		$94K Hold
7
– – ﹤0.01% 3015
2016
Q2 		$103K Hold
7
– – ﹤0.01% 3052
2016
Q1 		$84K Hold
7
– – ﹤0.01% 3001
2015
Q4 		$132K Hold
7
– – ﹤0.01% 3023
2015
Q3 		$91K Hold
7
– – ﹤0.01% 3044
2015
Q2 		$116K Buy
+7
New +$149K ﹤0.01% 3041

Other funds holding AGRX

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
NIM
Needham Investment Management New York $3.33B AUM 163.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Charles Schwab's AGRX Position: Q3 2021 in Review

Charles Schwab sold out of Agile Therapeutics (AGRX) in Q3 2021, closing a stake of 16 shares — an estimated $42K sold.

Charles Schwab first reported a position in AGRX in Q2 2015 and held it in 13 quarters. The position peaked at $524K in Q3 2020. 49 funds tracked by Wall St. Rank hold AGRX as of Q3 2021.

  • Charles Schwab reported no remaining Agile Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Charles Schwab sold 16 Agile Therapeutics shares in Q3 2021, an estimated $42K.
  • Charles Schwab first reported a position in Agile Therapeutics in Q2 2015 and held it in 13 quarters.
  • Charles Schwab's Agile Therapeutics position peaked at $524K in Q3 2020.
  • 49 funds tracked by Wall St. Rank held Agile Therapeutics as of Q3 2021.

Based on Charles Schwab's 13F filing for Q3 2021, filed 16 Nov 2021.